A recent study indicates that people who come off new weight-loss injections like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who stop conventional lifestyle programs.
Findings released in a prominent health publication demonstrates that while overweight people can lose a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using such drugs must be informed of the danger of rapid weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
That rate of regain implies a return to starting mass in about one and a half years.
Weighing Approaches
The analysis, which reviewed dozens of studies involving thousands of patients, compared the outcomes of these new drugs with other pills.
The team emphasize that people who lose weight through lifestyle changes alone generally see a more gradual creep back—perhaps 0.1 kg a month—after stopping.
Understanding the Rapid Regain
Experts suggest the mechanism of the jabs accounts for the amplified weight return.
These medications mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than normal could lead to the system to produce less of its own natural hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement results in hunger is unsuppressed, making overeating much more probable."
A Lifelong Condition?
Health authorities advise the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, due to the high risk of relapse, the treatment should be considered long-term.
This view is echoed by drug manufacturers, who state that the results "highlight the long-term nature of excess weight," similar to managing diseases like diabetes.
User Experiences
Individuals who have discontinued the jabs report a sudden return of cravings.
"It felt as if a switch that goes on and I was suddenly extremely hungry," said a patient.
This difficulty is worsened if users have not developed lasting lifestyle or habit modifications during therapy.
Growing Adoption
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is more common among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and maintained weight loss relies on integrated lifestyle support.
